Kirsten Craven

Selecting the right system for metabolite identification

Jul 14, 2023 | Blogs, LC, Pharma, SCIEX OS software, ZenoTOF 7600 system | 0 comments

Read Time: 3 minutes

So, you need a new liquid chromatography-mass spectrometry (LC-MS) system for your metabolite identification (metID) studies, and you are not sure which option is right for you. This blog provides an overview of the metID solutions offered by SCIEX, so you can make the best decision for your organization.

This is the first in a series of blogs intended to help you choose a system that meets your pharmaceutical research and development needs. We hope you find their guidance useful.

Let’s start with a simple question: Which of the following would help you sleep well at night?

A: knowing your batch of samples will be complete by your deadline
B: a clear identification of the site of metabolism for those extra complex samples

We have great news for you: SCIEX has solutions for enabling both A and B. Let’s take a closer look.

Scenario A
Let’s say you are looking for a system that will run larger batches of samples, and your analytes typically fragment well using collision-induced dissociation (CID), allowing confident identification of the site of metabolism without the need for additional confirmatory testing.

For a complex analysis, the requirements are relatively straightforward, and the priorities are probably ease of use and a robust system that does the job day in and day out. For this scenario, SCIEX recommends using the ExionLC 2.0+ system coupled to the X500R QTOF system, SCIEX OS software and maintenance with SCIEX service and support.
The workflow described in the technical note Targeted high-resolution metabolite screening workflows demonstrates the performance you can expect from this solution.

Scenario B
Suppose you have several samples where clear identification of the site of metabolism is not possible using CID. In this case, the use of a secondary analytical technique, such as nuclear magnetic resonance (NMR), is often required to meet regulatory requirements. Since this approach can be both time-consuming and expensive, an LC-MS system with more analytical power is ideal. Potent therapeutics is another common challenge in this type of scenario, which makes method sensitivity a key requirement for detecting low-abundant metabolites.

In these circumstances, SCIEX recommends using the ExionLC 2.0+ system coupled to the ZenoTOF 7600 system, SCIEX OS software and maintenance with SCIEX service and support.

The ZenoTOF 7600 system features the Zeno trap for enhanced sensitivity and electron activated dissociation (EAD) as a complementary fragmentation option. EAD typically fragments the metabolite in different locations, which can provide the additional information required for clear identification of the site of metabolism from a single analytical technique.

The workflow described in the technical note Confident characterization and identification of glucuronide metabolites using diagnostic fragments from electron activated dissociation (EAD) is a useful example of this solution.

Learn more
For more information on the options SCIEX offers for metID, please speak to your account manager or visit our web page on comprehensive metID.

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

Kirsten Craven

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

0 Comments